Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Comparative Evaluation of Survival Outcomes

Strategic Insights -

Recent research has shed new light on the effectiveness of high-dose biologically effective dose (BED) versus standard dose regimens in stereotactic body radiotherapy (SBRT) for localized prostate cancer. Investigators compared the safety and efficacy of high-dose BED versus standard dose regimens in a retrospective analysis of prostate-localized SBRT patients from two institutions. The results indicated that escalating the biologically effective dose above standard levels did not yield a significant improvement in tumor control or survival outcomes compared to conventional SBRT dosing for localized prostate cancer.

Key Takeaways:

  • The study compared the safety and efficacy of high-dose BED versus standard dose regimens in stereotactic body radiotherapy (SBRT) for localized prostate cancer using a propensity score matching (PSM) analysis.
  • The high-dose group (n=12) received high-dose BED (250Gy), and the control group (n=119) received standard dose regimens according to NCCN guidelines (35-37.5 Gy/5f, BED 198.3-225Gy).
  • The study found no significant improvement in tumor control or survival outcomes in patients treated with high-dose BED compared to standard dose regimens.
  • Patients with pre-existing health conditions were less likely to develop distant metastasis, and most patients tolerated SBRT with minimal toxicity.

Statistics:

  • 66.7% OS rate in the high-dose group vs. 83.4% in controls (p=0.402)
  • 88.9% CSS rate in the high-dose group vs. 90.5% in controls (p=0.480)
  • 91.7% 7-year bPFS rate in the high-dose group vs. 67.4% in controls (p=0.497)
  • 100% 7-year local control rate in the high-dose group vs. 95.1% in controls (p=0.569)
  • 91.7% 7-year distant metastasis-free survival rate in the high-dose group vs. 81.6% in controls (p=0.918)

Sources:

  • Analysis of standard vs dose-escalated stereotactic body radiation therapy in localized prostate cancer: a comparative evaluation of survival outcomes. Frontiers in Immunology, 2025;16:1654174.
  • NewsRx. New Prostate Cancer Study Findings Have Been Reported by Researchers at First Affiliated Hospital (Analysis of standard vs dose-escalated stereotactic body radiation therapy in localized prostate cancer: a comparative evaluation of survival ...). Cancer Weekly. September 16, 2025; p 2360.